<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="122969" href="/d/html/122969.html" rel="external">see "Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="123108" href="/d/html/123108.html" rel="external">see "Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53777427"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Trikafta</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397557"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Trikafta</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53765944"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cystic Fibrosis Transmembrane Conductance Regulator Corrector;</li>
<li>
                        Cystic Fibrosis Transmembrane Conductance Regulator Potentiator</li></ul></div>
<div class="block doa drugH1Div" id="F53836206"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Trikafta is supplied as 2 separate products packaged together: Elexacaftor/tezacaftor/ivacaftor (orange capsule-shaped tablets) in a fixed-dose combination and ivacaftor (blue capsule-shaped tablets).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis: Oral:</b> 2 tablets (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet) in the morning and one ivacaftor 150 mg tablet in the evening, approximately 12 hours apart.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Morning dose: If ≤6 hours since the missed morning dose, take the missed dose as soon as possible and continue the original schedule. If &gt;6 hours since the missed morning dose, take the missed dose as soon as possible and do <b>not</b> take the evening dose. The next scheduled morning dose should be taken at the usual time.</p>
<p style="text-indent:-2em;margin-left:4em;">Evening dose: If ≤6 hours since the missed evening dose, take the missed dose as soon as possible and continue the original schedule. If &gt;6 hours since the missed evening dose, do <b>not</b> take the missed dose. The next scheduled morning dose should be taken at the usual time.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information</p></div>
<div class="block dora drugH1Div" id="F53839088"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/min/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/min/1.73 m<sup>2</sup>: There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doha drugH1Div" id="F53839089"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B): Use only if the benefits outweigh the risks.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1: Reduce dose to 2 tablets (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet) in the morning (omit the evening ivacaftor dose).</p>
<p style="text-indent:-2em;margin-left:6em;">Day 2: Reduce dose to 1 tablet (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet) in the morning (omit the evening ivacaftor dose).</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3 and thereafter: Alternate between day 1 and day 2 dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Use not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment: </i> ALT/AST &gt;5 × ULN or ALT/AST &gt;3 × ULN with bilirubin &gt;2 × ULN: Interrupt therapy until resolved; consider the benefits and risks prior to resuming.</p></div>
<div class="block doe drugH1Div" id="F53839150"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Has not been studied.</p></div>
<div class="block dop drugH1Div" id="F53785641"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="122969" href="/d/html/122969.html" rel="external">see "Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Trikafta is supplied as 2 separate products packaged together: Elexacaftor/tezacaftor/ivacaftor in a fixed-dose combination co-packaged with ivacaftor; use caution when selecting dosage form; multiple strengths are available; appropriate strength is dependent on patient age and weight.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis (CF): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to &lt;6 years: Oral granules:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;14 kg: Elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg per packet and ivacaftor 59.5 mg per packet:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 1 packet (total dose of elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning and one ivacaftor 59.5 mg packet in the evening approximately 12 hours apart.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥14 kg: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per packet and ivacaftor 75 mg packet:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 1 packet (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one ivacaftor 75 mg packet in the evening approximately 12 hours apart.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 to &lt;12 years: Oral tablets:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;30 kg: Elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg per tablet and ivacaftor 75 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 2 tablets (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one ivacaftor 75 mg tablet in the evening, approximately 12 hours apart.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥30 kg: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet and ivacaftor 150 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 2 tablets (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one ivacaftor 150 mg tablet in the evening, approximately 12 hours apart.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet and ivacaftor 150 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 2 tablets (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one ivacaftor 150 mg tablet in the evening, approximately 12 hours apart.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Morning dose: If ≤6 hours since the missed morning dose, take the missed dose as soon as possible and continue the original schedule. If &gt;6 hours since the missed morning dose, take the missed dose as soon as possible and do <b>not</b> take the evening dose. The next scheduled morning dose should be taken at the usual time.</p>
<p style="text-indent:-2em;margin-left:6em;">Evening dose: If ≤6 hours since the missed evening dose, take the missed dose as soon as possible and continue the original schedule. If &gt;6 hours since the missed evening dose, do <b>not</b> take the missed dose. The next scheduled morning dose should be taken at the usual time.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53785642"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≤30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling; use with caution; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F53785643"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use caution when selecting dosage form; multiple strengths are available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to initiation (baseline): </i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: Children ≥2 years and Adolescents: Oral: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment: <b>Note:</b> Use not recommended unless benefits exceed the risk.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;14 kg: Elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg per packet and ivacaftor 59.5 mg per packet:</p>
<p style="text-indent:-2em;margin-left:10em;">Days 1 to 3: Oral: 1 packet (total dose elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 4: No dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Days 5 and 6: Oral: 1 packet (total dose of elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 7: No dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Repeat same cycle weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥14 kg: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per packet and ivacaftor 75 mg per packet:</p>
<p style="text-indent:-2em;margin-left:10em;">Days 1 to 3: Oral: 1 packet (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 4: No dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Days 5 and 6: Oral: 1 packet (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 7: No dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Repeat same cycle weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight &lt;30 kg: Elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg per tablet and ivacaftor 75 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">Day 1: Oral: 2 tablets (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 2: Oral: 1 tablet (total dose of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 3 and subsequent days: Continue alternating Day 1 and Day 2 regimens thereafter.</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥30 kg: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet and ivacaftor 150 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">Day 1: Oral: 2 tablets (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 2: Oral: 1 tablet (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:10em;">Day 3 and subsequent days: Continue alternating Day 1 and Day 2 regimens thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg per tablet and ivacaftor 150 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Oral: 2 tablets (total dose of elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 150 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2: Oral: 1 tablet (total dose of elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) once in the morning; omit the evening dose of ivacaftor.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 3 and subsequent days: Continue alternating Day 1 and Day 2 regimens thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Children ≥2 years and Adolescents: Oral: Do not administer; use has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment: </i>Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;5 × ULN: Temporarily discontinue elexacaftor/tezacaftor/ivacaftor; may resume if elevated transaminases are resolved and after assessing benefits versus risks of continued treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT or AST &gt;3 × ULN with concomitant bilirubin &gt;2 × ULN: Temporarily discontinue elexacaftor/tezacaftor/ivacaftor; may resume if elevated transaminases are resolved and after assessing benefits versus risks of continued treatment.</p></div>
<div class="block adr drugH1Div" id="F53777470"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults. Also see Tezacaftor and Ivacaftor, and Ivacaftor.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14%), diarrhea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased indirect serum bilirubin (11%), increased serum transaminases (11%; including increased serum alanine aminotransferase [10%], increased serum aspartate aminotransferase [9%])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased systolic blood pressure (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (2% to 5%), eczema (2% to 5%), pruritus (2% to 5%), skin rash (10%; females 16%, males 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (2% to 5%), flatulence (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (2% to 5%), urinary tract infection (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: C-reactive protein increased (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased direct serum bilirubin (3%), increased serum bilirubin (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (9%), pharyngitis (2% to 5%), respiratory tract infection (2% to 5%), rhinitis (7%), rhinorrhea (8%), sinusitis (5%), tonsillitis (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hepatic: Hepatic injury</p></div>
<div class="block coi drugH1Div" id="F53765947"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to elexacaftor, tezacaftor, ivacaftor, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53836201"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataracts: Noncongenital lens opacities and cataracts have been reported in pediatric patients treated with ivacaftor; other risk factors were present in some cases (eg, corticosteroid use, exposure to radiation), but a possible risk related to ivacaftor cannot be excluded. Baseline and follow-up ophthalmological examinations are recommended in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Liver failure leading to transplantation in patients with cirrhosis and portal hypertension has been reported; avoid use when possible in patients with preexisting liver disease (eg, presence of cirrhosis, portal hypertension, ascites, hepatic encephalopathy). Increased LFTs, sometimes requiring hospital intervention, may occur even in patients without preexisting liver disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with elexacaftor/tezacaftor/ivacaftor use. If signs and symptoms of severe hypersensitivity occur, discontinue use and treat appropriately; consider risk versus benefit prior to resuming therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in patients with moderate impairment (Child-Pugh class B); use not recommended in severe impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data.</p></div>
<div class="block prod-avail drugH1Div" id="F58119710"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Trikafta oral granules: FDA approved April 2023; availability anticipated May 2023. Information pertaining to this product within the monograph is pending revision. Trikafta oral granules are indicated for use in pediatric patients 2 to &lt;6 years of age. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F53777428"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trikafta: Elexacaftor 100 mg, ivacaftor 75 mg, and tezacaftor 50 mg (56 ea) plus ivacaftor 150 mg (28 ea) (84 ea); Elexacaftor 50 mg, ivacaftor 37.5 mg, and tezacaftor 25 mg (56 ea) plus ivacaftor 75 mg (28 ea) (84 ea) [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trikafta: Elexacaftor 100 mg, ivacaftor 75 mg, and tezacaftor 50 mg (7 ea) plus ivacaftor 75 mg (7 ea) (14 ea); Elexacaftor 80 mg, ivacaftor 60 mg, and tezacaftor 40 mg (7 ea) plus ivacaftor 59.5 mg (7 ea) (14 ea) [unflavored flavor]</p></div>
<div class="block geq drugH1Div" id="F53777426"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53793961"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Trikafta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-25-37.5 &amp; 75 mg (per each): $379.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100-50-75 &amp; 150 mg (per each): $379.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Therapy Pack</b> (Trikafta Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80-40-60 &amp; 59.5 mg (per each): $568.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100-50-75 &amp; 75 mg (per each): $568.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397558"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trikafta: Elexacaftor 100 mg, ivacaftor 75 mg, and tezacaftor 50 mg (56 ea) plus ivacaftor 150 mg (28 ea) (84 ea); Elexacaftor 50 mg, ivacaftor 37.5 mg, and tezacaftor 25 mg (56 ea) plus ivacaftor 75 mg (28 ea) (84 ea) [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trikafta: Elexacaftor 100 mg, ivacaftor 75 mg, and tezacaftor 50 mg (7 ea) plus ivacaftor 75 mg (7 ea) (56 ea); Elexacaftor 80 mg, ivacaftor 60 mg, and tezacaftor 40 mg (7 ea) plus ivacaftor 59.5 mg (7 ea) (56 ea)</p></div>
<div class="block accres drugH1Div" id="F53983992"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Product is only available via authorized pharmacies and distributors. Further information is available at https://www.vrtx.com/authorized-distributors.</p></div>
<div class="block adm drugH1Div" id="F53839091"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Swallow tablets whole. Administer with a fat-containing meal or snack (eg, those prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, or meats).</p></div>
<div class="block admp drugH1Div" id="F53785644"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with fat-containing food (eg, eggs, butter, oils, cheese, nuts, peanut butter, meats, whole-milk dairy products). Avoid food or drink containing grapefruit.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Swallow tablet whole.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral granules: Mix entire contents of each packet with 5 mL of age-appropriate soft food (eg, applesauce, pureed fruit or vegetables, yogurt) or liquid (eg, water, milk, juice) that is at or below room temperature. Once mixed, consume within 1 hour.</p></div>
<div class="block use drugH1Div" id="F53765946"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cystic fibrosis:</b> Treatment of cystic fibrosis in patients ≥2 years of age who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.</p></div>
<div class="block cyt drugH1Div" id="F53808766"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F53808763"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: Elexacaftor, Tezacaftor, and Ivacaftor may increase the serum concentration of Berotralstat. Berotralstat may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: Decrease berotralstat to 110 mg daily. Elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Management: Administer elexacaftor/tezacaftor/ivacaftor in the morning, twice a week, 3 to 4 days apart, with no evening doses of ivacaftor alone. Specific dosing varies by age and weight. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Digoxin.  Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glimepiride: Elexacaftor, Tezacaftor, and Ivacaftor may increase the serum concentration of Glimepiride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlipiZIDE: Elexacaftor, Tezacaftor, and Ivacaftor may increase the serum concentration of GlipiZIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the serum concentration of ivacaftor may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: May enhance the adverse/toxic effect of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the risk for rash may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: Elexacaftor, Tezacaftor, and Ivacaftor may increase the serum concentration of Lefamulin. Lefamulin may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: Consider alternatives to this combination when possible. If combined, monitor for increased lefamulin toxicities and decrease the elexacaftor/tezacaftor/ivacaftor dose. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with P-glycoprotein (P-gp) inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Elexacaftor, Tezacaftor, and Ivacaftor may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F53836203"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase exposure of elexacaftor, tezacaftor, or ivacaftor. Management: Avoid food or drink containing grapefruit during treatment.</p></div>
<div class="block pri drugH1Div" id="F53836199"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ivacaftor crosses the placenta (Trimble 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the ivacaftor monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F53836200"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor is present in breast milk (Trimble 2018); excretion of elexacaftor and tezacaftor is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to the ivacaftor monograph for additional information.</p></div>
<div class="block dic drugH1Div" id="F53839090"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with fat-containing food (eg, eggs, butter, peanut butter, whole-milk dairy products [eg, whole milk, cheese, yogurt]). Avoid food or drink containing grapefruit during treatment.</p></div>
<div class="block mop drugH1Div" id="F53839093"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs at baseline, every 3 months during the first year, then annually thereafter (more frequent monitoring should be considered in patients with cirrhosis, portal hypertension, or a history of hepatobiliary disease or LFT elevations). Baseline and follow-up ophthalmological examinations are recommended in pediatric patients.</p></div>
<div class="block pha drugH1Div" id="F53836205"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor and tezacaftor facilitate the cellular processing and trafficking of normal and select mutant forms of cystic fibrosis transmembrane conductance regulator (CFTR) (including F508del-CFTR) to increase the amount of mature CFTR protein delivered to the cell surface.</p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface.</p></div>
<div class="block phk drugH1Div" id="F53785638"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The following pharmacokinetic parameters are based on studies in patients with cystic fibrosis ≥12 years of age and adults. Exposures in children ≥6 years are within the range shown in patients ≥12 years.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: AUC increased 1.9- to 2.5-fold with a moderate-fat meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: Food increases exposure 2.5- to 4-fold.</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: No significant effect from food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: 53.7 ± 17.7 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: 293 ± 89.8 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: 82 ± 22.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: ~99%.</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: ~99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: Primarily via CYP3A4/5 to active metabolite M23-ELX (similar potency to parent compound).</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: Primarily via CYP3A4/5 to active metabolite M1-IVA (significantly less potent compared to parent compound).</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: Primarily via CYP3A4/5 to active metabolite M1-TEZ (similar potency to parent compound).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: 80%.</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: Not determined.</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: Not determined.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: 27.4 ± 9.31 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: 15 ± 3.92 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: 25.1 ± 4.93 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: Median: 6 hours (range: 4 to 12 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: Median: 4 hours (range: 3 to 6 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: Median: 3 hours (range: 2 to 4 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Elexacaftor: Urine (0.23%); feces (~87% primarily as metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Ivacaftor: Urine (6.6%); feces (~88%).</p>
<p style="text-indent:-2em;margin-left:4em;">Tezacaftor: Urine (14%, &lt;1% as unchanged drug); feces (72% as unchanged drug or M2-TEZ metabolite).</p></div>
<div class="block phksp drugH1Div" id="F55060910"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Hepatic impairment:</b> In patients with moderate impairment (Child-Pugh class B), elexacaftor AUC and C<sub>max</sub> increased 25% and 12%, respectively; M23-ELX AUC and C<sub>max</sub> increased 73% and 70%, respectively; combined elexacaftor and M23-ELX AUC and C<sub>max</sub> increased 36% and 24%, respectively; tezacaftor AUC increased 20% but C<sub>max</sub> similar; and ivacaftor AUC increased 1.5-fold and C<sub>max</sub> increased 10% compared to healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521939"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Trilexa | Trixacar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Trikafta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio | Trikafta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kaftrio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Trikafta.3">
<a name="Trikafta.3"></a>Trikafta (elexacaftor/tezacaftor/ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trikafta.2">
<a name="Trikafta.2"></a>Trikafta (elexacaftor/tezacaftor/ivacaftor) [product monograph]. Toronto, Ontario, Canada: Vertex Pharmaceuticals (Canada) Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866531">
<a name="29866531"></a>Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR Jr. Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding. <i>J Cyst Fibros.</i> 2018;17(6):779-782. doi: 10.1016/j.jcf.2018.05.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/elexacaftor-tezacaftor-and-ivacaftor-co-packaged-with-ivacaftor-drug-information/abstract-text/29866531/pubmed" id="29866531" target="_blank">29866531</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 122968 Version 116.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
